Literature DB >> 12619159

Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases.

Francesco Albano1, Giorgina Specchia, Luisa Anelli, Antonella Zagaria, Clelia Tiziana Storlazzi, Caterina Buquicchio, Maria Grazia Roberti, Vincenzo Liso, Mariano Rocchi.   

Abstract

The Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML) and is observed in more than 90% of CML cases. At diagnosis, in 5-10% of CML patients the Ph chromosome is derived from variant translocations other than the standard t(9;22). Deletions adjacent to the translocation junction on the derivative chromosome 9 were recently described by different groups. The deletions may identify a subgroup with a worse prognosis. The presence of similar deletions on the third derivative other than the 9 and 22 chromosomes in CML with variant translocation has never been investigated. We studied three cases of CML variants showing relatively large deletions on the third chromosome involved in the translocation. Known tumor-suppressor genes (TSGs) or genes involved in signal transduction and in the modulation of cell proliferation were found to be located inside these deleted regions. As an alternative to Knudson's two-hit model, the "haplo-insufficiency" hypothesis suggests that the deletion of a single allele of a TSG can play an important role in tumor progression. Our findings suggest that great attention should be paid to the molecular cytogenetic characterization of variant t(9;22) CML patients to unveil fully the biological heterogeneity of CML. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12619159     DOI: 10.1002/gcc.10183

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.

Authors:  Ayda Bennour; Ines Ouahchi; Yosra Ben Youssef; Monia Zaier; Mohamed Adnéne Laatiri; Imed Harrabi; Balkis Meddeb; Moez Elloumi; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Med Oncol       Date:  2011-04-03       Impact factor: 3.064

2.  Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.

Authors:  Francesco Albano; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Paola Casieri; Antonella Russo Rossi; Laura Vicari; Vincenzo Liso; Mariano Rocchi; Giorgina Specchia
Journal:  Mol Cancer       Date:  2010-05-25       Impact factor: 27.401

3.  Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia.

Authors:  Misti Samaiya; Sameer Bakhshi; Abhay A Shukla; Lalit Kumar; Shyam S Chauhan
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

4.  Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East.

Authors:  Akbar Safaei; Ahmad Monabati; Moeinadin Safavi; Ali Atashabparvar; Marzieh Hosseini
Journal:  Blood Res       Date:  2018-03-27

Review 5.  A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature.

Authors:  Yuka Torii; Kana Nanjo; Tomomi Toubai; Masashi Hosokawa; Ryo Sato; Akane Yamada; Keiko Aizawa; Masahito Himuro; Satoshi Ito; Masakazu Yamamoto; John Magenau; Ryan Wilcox; Kenichi Ishizawa
Journal:  J Med Case Rep       Date:  2021-05-25

6.  Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients.

Authors:  Cosimo Cumbo; Luciana Impera; Crescenzio Francesco Minervini; Paola Orsini; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Giuseppina Tota; Angela Minervini; Paola Casieri; Claudia Brunetti; Antonella Russo Rossi; Elisa Parciante; Giorgina Specchia; Francesco Albano
Journal:  Oncotarget       Date:  2018-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.